Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCreo Medical Regulatory News (CREO)

Share Price Information for Creo Medical (CREO)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 35.25
Bid: 35.00
Ask: 35.50
Change: -0.50 (-1.40%)
Spread: 0.50 (1.429%)
Open: 35.75
High: 35.75
Low: 35.25
Prev. Close: 35.75
CREO Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director/PDMR Shareholding

25 Mar 2010 07:00

RNS Number : 1442J
China Real Estate Opportunities PLC
25 March 2010
 



 

 

 

China Real Estate Opportunities plc

 

Directors / PDMR Shareholding

 

In accordance with Rule 17 of the AIM Rules, China Real Estate Opportunities plc ("CREO" or the "Company") announces that on 24 March 2010 it was notified by various directors and a significant shareholder, as detailed below, of share purchases made as part of the recent placing by the Company announced on 23 March 2010. Following the completion of the buy back of 1,500,000 shares for cancellation announced on the same day, the issued share capital of the Company is 48,036,004.

 

Richard Barrett, a director of the Company, notified the Company that on 23 March 2010 he purchased 131,510 ordinary shares of no par value in the Company at a price of 330p per share. This purchase represents 0.27 per cent of the issued share capital of the Company.

 

Following the share purchase, Richard Barrett has an interest in 8,955,518 ordinary no par value shares representing 18.64 per cent of the issued share capital of the Company.

 

In addition, the Company was notified by Mr Barrett that members of his family purchased 119,000 ordinary no par value shares representing 0.25 per cent of the issued share capital of the Company. Following the share purchase, members of Mr Barrett's family have an interest in 131,891 ordinary no par value shares representing 0.27 per cent of the issued share capital of the Company.

 

Rory Williams, a director of the Company, notified the Company that on 23 March 2010 he purchased 55,000 ordinary shares of no par value in the Company at a price of 330p per share. This purchase represents 0.11 per cent of the issued share capital of the Company.

 

Following the share purchase, Mr Williams has an interest in 175,000 ordinary no par value shares representing 0.36 per cent of the issued share capital of the Company.

 

Richard David, a director of the Company, notified the Company that on 23 March 2010 he purchased 17,500 ordinary shares of no par value in the Company at a price of 330p per share. This purchase represents 0.04 per cent of the issued share capital of the Company.

 

Following the share purchase, Mr David has an interest in 30,000 ordinary no par value shares representing 0.06 per cent of the issued share capital of the Company.

 

Ray Horney, a director of the Company, notified the Company that on 23 March 2010 Barclays Wealth Trustees (Guernsey) Limited, acting as Trustee of certain trusts under which Mr Horney and / or members of his family are beneficiaries, purchased 75,000 ordinary shares of no par value in the Company at a price of 330p per share. This purchase represents 0.16 per cent of the issued share capital of the Company.

 

Following the share purchase, Mr Horney has an interest in 2,825,000 ordinary no par value shares representing 5.88 per cent of the issued share capital of the Company.

 

In addition the Company was notified by Mr Horney that a member of his family purchased 45,000 ordinary no par value shares representing 0.09 per cent of the issued share capital of the Company. This purchase represents the total interest in the Company following the share purchase.

 

On the same day, the Company was notified by John Ronan, a significant shareholder of the Company and a 50 per cent shareholder of Treasury Holdings, that a member of his family purchased 55,000 ordinary shares of no par value in the Company at a price of 330p per share. This purchase represents 0.11 per cent and represents their total interest in the Company following the share purchase.

 

 

 

 

 

 

Contact:

CREO

Ray Horney, Chairman

Tel: + 44 (0) 1273 775 225

 

Sarah Moriarty, Investor Relations

Tel: + 353 1 618 9455

 

 

Matrix Corporate Capital LLP

Paul Fincham, Rob Naylor

Tel: + 44 (0) 20 3206 7000

 

 

Davy

Des Carville

Tel: +353 1 679 6363

 

 

Citigate Dewe Rogerson Limited 

Tom Baldock

Tel: 44 (0) 20 7638 9571

 

 

Murray Consultants

Ed Micheau

Tel: + 353 1 498 0300

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSLLFFDVSISFII
Date   Source Headline
25th Apr 20247:00 amRNSNotice of Results
24th Apr 20247:00 amRNSNHS Speedboat data demonstrates savings
20th Mar 20244:52 pmRNSHolding(s) in Company
19th Mar 20247:00 amRNSWelsh Labour Leader visits Creo’s facilities
13th Mar 20243:05 pmRNSHolding(s) in Company
11th Mar 20242:00 pmRNSLTIP Awards
6th Mar 20244:35 pmRNSHolding(s) in Company
1st Mar 20247:00 amRNSMicrowave Lung Ablation Update
7th Feb 20249:12 amRNSTrading Update - Replacement
7th Feb 20247:00 amRNSTrading Update
5th Feb 20247:00 amRNSStrategic Collaboration with Khalifa University
31st Jan 20247:00 amRNSSpeedboat® UltraSlim roll-out reaches Asia Pacific
22nd Jan 20247:00 amRNSAward of Shares under Share Incentive Plan
10th Jan 20247:00 amRNSFirst use of Speedboat® UltraSlim in Latin America
15th Dec 20237:00 amRNSFirst use of Speedboat® UltraSlim in the USA
13th Dec 20237:00 amRNSFirst European Speedboat® UltraSlim procedure
7th Nov 20237:00 amRNSCapital Markets Day
1st Nov 20237:00 amRNSSpeedboat® UltraSlim: US FDA Clearance
25th Oct 20237:00 amRNSSB UltraSlim: EU launch accelerated by 18 months
16th Oct 202310:16 amRNSChange of Nominated Adviser and Joint Broker
12th Oct 20237:00 amRNSInvestor Presentation
12th Sep 20237:00 amRNSHalf-year Report
5th Sep 20237:00 amRNSNotice of Results
16th Aug 20237:00 amRNSRoyal Oldham SSD service update
3rd Aug 20237:00 amRNSHalf Year Trading Update
28th Jul 20237:00 amRNSTotal Voting Rights
24th Jul 202310:40 amRNSAward of Shares under Share Incentive Plan
6th Jul 202311:33 amRNSIssue of Equity and TVR
27th Jun 20231:15 pmRNSResult of AGM
27th Jun 20237:00 amRNSAGM Statement & Directorate Succession Planning
26th Jun 20237:00 amRNSFirst upper GI Speedboat procedure in Europe
22nd Jun 20237:00 amRNSAppointment of Marco Scarci
19th Jun 20237:00 amRNSSpeedboat Inject upper GI clearance in Europe
1st Jun 20237:00 amRNSSpeedboat™ Inject selected by NICE for assessment
26th May 20237:00 amRNSPosting of Annual Report and Notice of AGM
23rd May 20237:00 amRNSFirst in-human milestone for MicroBlate™ Flex
17th May 20237:00 amRNSRoyal Oldham Hospital Agreement
15th May 20237:00 amRNSAttendance at Digestive Disease Week
26th Apr 20237:00 amRNSFinal Results
14th Apr 20237:00 amRNSAlbyn Medical earn out update
31st Mar 202310:45 amRNSTotal Voting Rights
31st Mar 20237:00 amRNSMicroBlate™ Flex clinical study
13th Mar 20236:13 pmRNSDirector/PDMR and PCA Share Dealings
13th Mar 20237:00 amRNSHolding(s) in Company
8th Mar 202310:25 amRNSResult of GM
6th Mar 202311:05 amRNSSecond Price Monitoring Extn
6th Mar 202311:00 amRNSPrice Monitoring Extension
21st Feb 202310:29 amRNSHolding(s) in Company
17th Feb 20232:05 pmRNSSecond Price Monitoring Extn
17th Feb 20232:00 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.